Anti-vegf therapy in diabetic macular oedema patients over four years
Description
OBJECTIVES: To evaluate visual acuity (VA) outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in diabetic macular oedema (DMO).
METHODS: In this retrospective cohort study, electronic medical records for all patients undergoing intravitreal injections (IVI) in a tertiary referral centre between March 2013 and October 2018 were analysed. Treatment response in terms of visual acuity outcomes were reported for all eyes over a 4-year observation period.
RESULTS: Our cohort includes 2614 DMO eyes of 1964 patients over 48 months. Cox proportional hazards modelling identified injection number (hazard ratio [HR] = 1.18), male gender (HR = 1.13), and baseline VA (HR = 1.09) as independent predictors to reach a favourable visual outcome of more than 70 Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Half of our cohort reached 70 letters 1.9 months after starting anti-VEGF therapy. Of those that reached 70 letters, 50% fell below 70 by 14.7 months.
CONCLUSION: To date, this is the largest single centre cohort study and over the longest observation period reporting on real-life outcomes of anti-VEGF in DMO. We have made an anonymised version of our dataset available on an open-source data repository as a resource for clinical researchers globally.
Notes
Files
200319_DMO_report1_anonymised.csv
Files
(5.1 MB)
Name | Size | Download all |
---|---|---|
md5:f1c20f49fd611f03ffa9440ec1039bb7
|
5.1 MB | Preview Download |
md5:5a9684cc1481f813f6951ba6cacad983
|
17.7 kB | Download |
Additional details
Related works
- Is cited by
- 10.1038/s41433-020-1048-0 (DOI)